Long Ideas - Synergy Pharmaceuticals (SGYP) is well-funded, with over $100 million in cash after its last capital raise, and the weakening biotech tape of late enables investors … Continue Reading
Read nowLong Ideas - Sunshine Heart has rallied 20% since dropping to $5.00 in mid-May following an equity financing. PropThink’s subscribers knew to buy the dip, and on Monday, … Continue Reading
Read nowLong Ideas - Cell therapy developers Athersys and Cytomedix target the immense stroke treatment market. Mr. Napodano laid out the theses for these two stem cell developers, although … Continue Reading
Read nowLong Ideas - Synergy’s equity financing, which wrapped up last Tuesday, put the company in a strong position for a partnership (or M&A) negotiation regarding plecanatide. The stock … Continue Reading
Read nowLong Ideas - On April 9, Synergy Pharmaceuticals (SGYP) reached a new 52-week intra-day high of $7.44, driven by a Cantor Fitzgerald analyst report highlighting more detailed trial … Continue Reading
Read nowLong Ideas - Since pricing its latest public offering at $5.50 two weeks ago, shares of Synergy Pharmaceuticals (SGYP) have failed to hold that print and are trading … Continue Reading
Read nowLong Ideas - Synergy Pharmaceuticals (NASDAQ:SGYP) released in an 8-k Thursday night that it has entered into an agreement with Ironwood Pharmaceuticals (NASDAQ:IRWD) for an exclusive worldwide license … Continue Reading
Read now